sábado, 22 de septiembre de 2018

Galectin Therapeutics buries bad news in the hype of a combination cancer drug trial

Galectin Therapeutics buries bad news in the hype of a combination cancer drug trial

Daily Recap

STAT Plus: Galectin Therapeutics buries bad news in the hype of a combination cancer drug trial

By ADAM FEUERSTEIN


NIH
The small biotech says new clinical trial data suggest its experimental cancer drug improves the efficacy of Merck’s Keytruda. Eye roll.

No hay comentarios:

Publicar un comentario